Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Divestment

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

- PMLiVE

Researchers develop immunotherapy to prevent prostate cancer treatment resistance

The second-most common cancer in the UK affects more than 52,000 men every year

- PMLiVE

ALX Oncology’s evorpacept shows promise as gastric cancer combination treatment

More than 6,500 new diagnoses of gastric cancer are made in the UK every year

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

GSK’s Jemperli combination approved by FDA for expanded endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

- PMLiVE

GSK’s RSV vaccine Arexvy recommended by CHMP for adults aged 50 to 59 years

The positive opinion comes just over a year after Arexvy was approved for those aged 60 and over

- PMLiVE

GSK and Flagship Pioneering partner in deal worth up to $7bn to discover medicines and vaccines

The companies aim to develop a portfolio of up to ten candidates

- PMLiVE

Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

- PMLiVE

AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader

The candidate has shown promising preclinical anti-tumour activity in drug- and TKI-resistant tumours

- PMLiVE

Ipsen gains ex-US rights to Day One’s brain cancer therapy in deal worth over $460m

Paediatric low-grade gliomas are the most common type of brain tumour diagnosed in children

- PMLiVE

Novartis and Dren Bio enter bispecific antibody partnership worth up to $3bn

The companies will aim to advance targeted myeloid engager programmes in oncology

- PMLiVE

ICR study on cell competition mechanism could lead to new ways of treating cancer

Female breast, lung, bowel and prostate cancers account for more than four in ten of all cancers worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links